AGM notes from a non-medic., page-17

"... the fact is the trials will ultimately determine if this is a good decision to hold or not."

True, but the evidence so far is pretty compelling. Not only are we being very successful with improved efficacy, but the safety profile is better every time. Keytrunda has shown some terrible side effects, like losing limbs!

I see no reason to sell. Especially as the conservative Edison values vla at $1.60, Bell Potter $1.81 and Roth $4.50 - so an average broker valuation of $2.63.